Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari Securities LLC, which acted as the lead underwriter for the Company’s underwritten initial public offering (the “Offering” or the “IPO”), has exercised in full the over-allotment option the Company granted to the underwriters an ...